Cytovale is a commercial-stage medical diagnostics company specializing in the development of early detection technologies for fast-moving and immune-mediated diseases. Their flagship product, the FDA-cleared IntelliSep test, provides rapid sepsis detection, helping hospitals enhance patient care and reduce costs. The company is focused on expanding the availability of this technology to emergency departments across the United States.
Leadership & Board
- Current Number of Employees
- 124
- Current LinkedIn Followers
- 17,625
Latest Estimated Valuation
- Total Amount Raised
- $100M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $100M
- Latest Funding Round
- Series D
Company Momentum
PositiveCytovale LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Cytovale had 124 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Cytovale had 17,625 followers as of November 2, 2026. The number of followers increased by 193 (1.11%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series D | $100.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Norwest Venture Partners | Series D |
| Sands Capital | Series D |
| Canada Pension Plan Investment Board | Series D |
| Global Health Investment Corporation | Series D |
| Breakout Ventures | Series D |
Similar Companies
A snapshot of private companies similar to Cytovale, helping you discover and navigate related company profiles.
Related News and Analysis
